Gene therapy readiness check: new study maps virus immunity in muscle disease patients
NCT ID NCT07633951
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will test blood samples from 450 people aged 6 to 60 with inherited neuromuscular diseases to see if they have antibodies that could block gene therapy viruses (AAVs). The goal is to understand how common these antibodies are and which patients might be good candidates for future gene therapies. No treatment is given; it is an observational study to gather important information.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENETIC DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
GENETHON
Évry, Île-de-France Region, 9100, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Stress-Busting program help VHL patients cope better?
- Testosterone levels linked to brain health in new genetic analysis
- 110,000 patients join massive DNA study to unlock disease secrets
- Scientists hunt for genes behind puberty problems
- NIH study aims to sharpen research skills by evaluating kids with genetic disorders
- Researchers hunt for muscle clues in rare dystrophy